Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q-CABG: Quercetin in Coronary Artery By-pass Graft Surgery
NCT04907253Phase 2Completed
- Sponsor
- Montréal Heart Institute
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronary artery disease (CAD) comparing Quercetin with Placebo (2 arms). Primary endpoints: Quercetin-associated Change in Surgery-associated Inflammation and Quercetin-associated Change in Surgery-associated Marker of Senescence. Started Jun 2021; status: completed.
02
Drugs
quercetin
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT04907253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04907253.